As Bristol Myers Squibb Co (Call) (BMY) Stock Price Declined, Ghost Tree Capital Has Upped Stake by $8.25 Million; Capital Management Decreased Its Anika Therapeutics (ANIK) Position by $4.14 Million; Valuation Declined

November 15, 2017 - By Henry Gaston

Ken Greenberg increased its stake in Bristol Myers Squibb Co (Call) (BMY) by 100% based on its latest 2017Q2 regulatory filing with the SEC. Ghost Tree Capital Llc bought 150,000 shares as the company’s stock declined 1.04% while stock markets rallied. The hedge fund run by Ken Greenberg held 300,000 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $16.75 million, up from 150,000 at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Bristol Myers Squibb Co (Call) for a number of months, seems to be bullish on the $100.25 billion market cap company. The stock declined 0.82% or $0.5 reaching $60.75 on the news. About 41,359 shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 15, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Capital Management Corp decreased its stake in Anika Therapeutics Inc (ANIK) by 58.07% based on its latest 2017Q2 regulatory filing with the SEC. Capital Management Corp sold 84,510 shares as the company’s stock declined 3.98% while stock markets rallied. The institutional investor held 61,030 shares of the medical and dental instruments company at the end of 2017Q2, valued at $3.01 million, down from 145,540 at the end of the previous reported quarter. Capital Management Corp who had been investing in Anika Therapeutics Inc for a number of months, seems to be less bullish one the $785.43M market cap company. The stock decreased 0.07% or $0.04 during the last trading session, reaching $53.57. About shares traded. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since November 15, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.




Ghost Tree Capital Llc, which manages about $481.10 million US Long portfolio, decreased its stake in Sage Therapeutics Inc (NASDAQ:SAGE) by 50,000 shares to 50,000 shares, valued at $3.98 million in 2017Q2, according to the filing. It also reduced its holding in Zimmer Biomet Hldgs Inc (ZMH) by 20,000 shares in the quarter, leaving it with 80,000 shares, and cut its stake in Neurocrine Biosciences Inc (NASDAQ:NBIX).

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It is negative, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Hartford Invest has 367,313 shares. Virginia Retirement System Et Al holds 126,700 shares. Paradigm Asset Mgmt Co Llc has 67,956 shares. The Ohio-based Keybank National Association Oh has invested 0.28% in Bristol-Myers Squibb Co (NYSE:BMY). Stock Yards Savings Bank & Tru reported 55,258 shares. Blackhill Cap Inc accumulated 468,325 shares. Bnp Paribas Asset Mgmt Sa, France-based fund reported 711,821 shares. Alphamark Advsrs Limited Liability Company has 900 shares for 0.02% of their portfolio. Woodley Farra Manion Port Mngmt stated it has 4,415 shares or 0.03% of all its holdings. Campbell Newman Asset reported 35,299 shares. Mcmillion Management Inc invested 2.34% in Bristol-Myers Squibb Co (NYSE:BMY). Point72 Asset Mgmt Lp has 0.03% invested in Bristol-Myers Squibb Co (NYSE:BMY). Agf accumulated 1.11 million shares. Boys Arnold Company Inc owns 11,049 shares. Rowland Company Invest Counsel Adv reported 5,825 shares or 0% of all its holdings.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 67 analyst reports since July 28, 2015 according to SRatingsIntel. Citigroup maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Wednesday, October 25. Citigroup has “Buy” rating and $72.0 target. As per Tuesday, September 29, the company rating was upgraded by UBS. The firm has “Neutral” rating given on Monday, May 23 by Hilliard Lyons. Piper Jaffray maintained Bristol-Myers Squibb Co (NYSE:BMY) on Friday, September 22 with “Hold” rating. Credit Suisse maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Wednesday, August 16. Credit Suisse has “Hold” rating and $58.0 target. The stock has “Market Perform” rating by BMO Capital Markets on Monday, January 25. Cowen & Co maintained the stock with “Hold” rating in Monday, September 18 report. The rating was maintained by Jefferies on Friday, September 15 with “Buy”. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Buy” rating given on Wednesday, August 23 by Jefferies. On Monday, July 17 the stock rating was maintained by Deutsche Bank with “Hold”.

More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Gurufocus.com which released: “Sheaff Brock Investment Advisors, LLC Buys DowDuPont Inc, AT&T Inc, Bristol …” on November 14, 2017, also Investorplace.com with their article: “Rating for Bristol-Myers Squibb Co (BMY) Drops….. Wilting Earnings Visibility” published on November 10, 2017, Economictimes.Indiatimes.com published: “Biocon arm widens partnership terms with Bristol-Myers Squibb” on November 14, 2017. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: Nasdaq.com and their article: “Sabal Trust CO Buys United Parcel Service Inc, Bristol-Myers Squibb Company …” published on October 18, 2017 as well as Marketwatch.com‘s news article titled: “Bristol-Myers Squibb shares decline 2% on Q3 profit miss, revenue beat …” with publication date: October 26, 2017.

Investors sentiment decreased to 1.14 in 2017 Q2. Its down 0.12, from 1.26 in 2017Q1. It fall, as 16 investors sold ANIK shares while 48 reduced holdings. 20 funds opened positions while 53 raised stakes. 12.24 million shares or 3.97% more from 11.77 million shares in 2017Q1 were reported. Btim holds 0.21% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK) for 261,992 shares. Hl Financial Ser Ltd Liability Co owns 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK) for 4,715 shares. Parametric Port Limited Liability Company invested in 10,194 shares. Piermont Capital Mgmt accumulated 39,824 shares. Bokf Na holds 9,213 shares. Jefferies Gru Ltd Llc invested in 4,108 shares or 0% of the stock. New Amsterdam Ltd Llc New York owns 65,536 shares or 0.69% of their US portfolio. Commercial Bank Of America De holds 0% or 20,218 shares in its portfolio. Blair William Il has 8,291 shares. 275,624 are owned by Columbia Wanger Asset Management Ltd Co. Us Bancshares De accumulated 0% or 1,060 shares. Rhumbline Advisers has invested 0% in Anika Therapeutics Inc (NASDAQ:ANIK). Jpmorgan Chase And accumulated 0% or 585 shares. American Int Group reported 10,801 shares. Royal State Bank Of Canada holds 39,950 shares or 0% of its portfolio.

Analysts await Anika Therapeutics Inc (NASDAQ:ANIK) to report earnings on February, 21. They expect $0.54 earnings per share, 0.00% or $0.00 from last year’s $0.54 per share. ANIK’s profit will be $7.92M for 24.80 P/E if the $0.54 EPS becomes a reality. After $0.46 actual earnings per share reported by Anika Therapeutics Inc for the previous quarter, Wall Street now forecasts 17.39% EPS growth.

Among 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Anika Therapeutics had 6 analyst reports since July 30, 2015 according to SRatingsIntel. Barrington Research initiated it with “Outperform” rating and $39 target in Monday, October 12 report. The firm has “Equal Weight” rating given on Friday, August 28 by First Analysis. The rating was downgraded by Northland Capital on Wednesday, April 27 to “Market Perform”. The firm earned “Hold” rating on Wednesday, August 26 by Zacks. As per Thursday, July 30, the company rating was maintained by Northland Capital. Northland Capital maintained Anika Therapeutics Inc (NASDAQ:ANIK) on Friday, February 26 with “Outperform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: